🔗 Share this article

As America proceeds with unprecedented revisions to its vaccine recommendations, one figure appears unexpectedly: Høeg, a Danish American sports physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her short time at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Schedule

Agency leaders were set to unveil sweeping revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a major change that would put the US at odds with a large portion of the international standard with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this year.

A Shift at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for discontinuing specific childhood shot schedules in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a population approximately the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent track record in medication creation, approval processes or management, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a large organization. She lacks background in industry regulation.”

Former directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who headed the center have had.”

CDER has an enormous workload at the FDA, she pointed out.

“Many people just pays attention on the innovative therapies, but the generic program authorizes thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and each of these need to be supervised,” she noted. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant management aspect to the position, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” the former official concluded.

Agency Reaction and Controversial Programs

In response to inquiries about Høeg’s fitness for the role and whether this selection signifies more teamwork among agency officials on vaccines, a spokesperson said that the “inquiries rely on inaccurate presumptions”.

“Her experience matches the functions of her job,” the representative stated, citing the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial one-day therapy clearance system that allegedly troubled her predecessors. “How are these therapies being picked for this expedited pathway? Who is making the calls?” Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he stated, “the agency seems to be moving towards more relaxed regulations of pharmaceuticals, with the exception of shots.”

Public History on Immunizations

With immunizations, Høeg has a clearer, if concerning, history, some experts observe. She released a analysis using unconfirmed crowd-sourced reports to determine the rate of myocarditis after COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the new government included altering guidelines for novel immunizations and discontinuing “non-essential” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She is an all-around ideologue who commences with her beliefs and works backwards to fit the data in a highly disingenuous, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|